Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

Fig. 7

FBXO22-mediated degradation of BACH1 enables maintenance of AML progression. A The indicated proteins were evaluated by Western blot in BM GFP+ cells from the indicated mice upon primary transplantation. The numbers show the quantification of protein levels. The asterisk represents a nonspecific band. B The percentages of GFP+ cells in PBMC (left) or BM (right) from the secondary recipients transplanted with Fbxo22+/+Bach1+/+, Fbxo22−/−Bach1+/+, Fbxo22+/+Bach1+/− and Fbxo22−/−Bach1+/− AML cells (n = 5). C Representative images of Giemsa-Wright staining for BM cells from the indicated mice upon the second transplantation. Quantification of the frequencies of blast cells was shown on the right. D, E Gross pathology (left, D), relative weights (right, D) and hematoxylin–eosin staining (E) of the livers and spleens from the secondary recipients (n = 5). F Survival curves and analysis of median survival from secondary recipients injected with Fbxo22+/+Bach1+/+, Fbxo22−/−Bach1+/+, Fbxo22+/+Bach1+/− and Fbxo22−/−Bach1+/− AML cells (n = 7). Error bars denote mean ± SD. Statistical significance was determined by two-tailed unpaired t test (B–D) or log-rank test (F), and the P values were shown. All animal experiments were repeated at least twice with similar results

Back to article page